CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 61 enrolled
Drug / intervention
bupropion +1 moredrug
Likely dose
bupropion 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00414167
NCT00414167Phase 3Completed
CompareCT.gov

Placebo-Controlled Trial of Bupropion for the Treatment of Binge Eating Disorder

Yale University·interventional·Posted Dec 21, 2006·Updated Apr 3, 2020

In Brief

A Phase 3 clinical trial evaluating bupropion and Placebo for Binge Eating Disorder and Obesity. Completed, enrolled 61 participants across 1 site.

Detailed Summary

This research study is designed to look at the effectiveness of bupropion for reducing binge eating in overweight persons with binge eating problems. Participants in the study will receive either bupropion or placebo ("sugar" pill, inactive medication) as an outpatient for eight weeks. In addition, participants will be given the option to receive 8 weeks of free behavioral weight loss treatment. This treatment, known to be effective for reducing binge eating and helping people lose weight, will be administered following the medication phase and at no cost. It is expected that compared to placebo, bupropion will produce greater reductions in binge eating.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBinge Eating Disorder, Obesity
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 21, 2006
Enrollment StartDec 1, 2005
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 19.5 years ago

Interventions

bupropiondrug

300 mg per day for 8 weeks

Placeboother

Placebo